Urogen Pharma (NASDAQ:URGN – Get Free Report) and Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Earnings & Valuation
This table compares Urogen Pharma and Dr. Reddy’s Laboratories”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Urogen Pharma | $188.73 million | 8.47 | -$153.49 million | ($1.98) | -16.53 |
| Dr. Reddy’s Laboratories | $3.58 billion | 3.31 | $456.00 million | $0.37 | 38.35 |
Dr. Reddy’s Laboratories has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Urogen Pharma and Dr. Reddy’s Laboratories, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
| Dr. Reddy’s Laboratories | 1 | 3 | 2 | 0 | 2.17 |
Urogen Pharma presently has a consensus price target of $52.38, indicating a potential upside of 60.07%. Dr. Reddy’s Laboratories has a consensus price target of $492.90, indicating a potential upside of 3,373.57%. Given Dr. Reddy’s Laboratories’ higher probable upside, analysts clearly believe Dr. Reddy’s Laboratories is more favorable than Urogen Pharma.
Volatility and Risk
Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Dr. Reddy’s Laboratories has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Insider and Institutional Ownership
91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy’s Laboratories shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy’s Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Urogen Pharma and Dr. Reddy’s Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Urogen Pharma | -51.73% | N/A | -43.79% |
| Dr. Reddy’s Laboratories | 8.56% | 7.91% | 5.29% |
Summary
Dr. Reddy’s Laboratories beats Urogen Pharma on 8 of the 14 factors compared between the two stocks.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
